Medline beats fiscal Q3 2026 estimates with EPS $0.44 (+42% YoY), revenue $7.9B (+10% YoY), raises full-year organic sales growth guidance, authorizes $1B buyback
https://finviz.com/stock?t=MDLN&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.